Last reviewed · How we verify

cisplatin + vinorelbine — Competitive Intelligence Brief

cisplatin + vinorelbine (cisplatin + vinorelbine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (platinum agent + vinca alkaloid). Area: Oncology.

phase 3 Chemotherapy combination (platinum agent + vinca alkaloid) DNA (cisplatin); tubulin/microtubules (vinorelbine) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

cisplatin + vinorelbine (cisplatin + vinorelbine) — Merck KGaA, Darmstadt, Germany. Cisplatin and vinorelbine work together as a chemotherapy combination to kill cancer cells by damaging DNA and disrupting microtubule formation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
cisplatin + vinorelbine TARGET cisplatin + vinorelbine Merck KGaA, Darmstadt, Germany phase 3 Chemotherapy combination (platinum agent + vinca alkaloid) DNA (cisplatin); tubulin/microtubules (vinorelbine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (platinum agent + vinca alkaloid) class)

  1. Merck KGaA, Darmstadt, Germany · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). cisplatin + vinorelbine — Competitive Intelligence Brief. https://druglandscape.com/ci/cisplatin-vinorelbine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: